1. Pujol, J. L., Barlesi, F., & Daures, J. P. (2006). Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer, 51(3), 335–345. doi: 10.1016/j.lungcan.2005.11.001 .
2. D'Addario, G., Pintilie, M., Leighl, N. B., Feld, R., Cerny, T., & Shepherd, F. A. (2005). Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. Journal of Clinical Oncology, 23(13), 2926–2936. doi: 10.1200/JCO.2005.03.045 .
3. Rajeswaran, A., Trojan, A., Burnand, B., & Giannelli, M. (2008). Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer, 59(1), 1–11. doi: 10.1016/j.lungcan.2007.07.012 .
4. Gettinger, S. N., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Juergens, R. A., et al. (2014). First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. Journal of Clinical Oncology, 32, 5s.
5. Rizvi, N. A., Garon, E. B., Patnaik, A., Gandhi, L., Leighl, N. B., Balmanoukian, A. S., et al. (2014). Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 32, 5s.